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Telomeres are repetitive sequences at the natural ends of linear eukaryotic chromosomes
that protect these from recognition as chromosome breaks. Their ability to do so critically
depends on the binding of sufficient quantities of functional shelterin, a six-unit protein
complex with specific and crucial roles in telomere maintenance and function. Insufficient
telomere length, leading to insufficient concentration of shelterin at chromosome ends, or
otherwise crippled shelterin function, causes telomere deprotection. While contributing to
aging-related pathologies, loss of telomere protection can act as a barrier to tumorigene-
sis, as dysfunctional telomeres activate DNA-damage-like checkpoint responses that halt
cell proliferation or trigger cell death. In addition, dysfunctional telomeres affect cancer
development and progression by being a source of genomic instability. Reviewed here are
the different approaches that are being undertaken to investigate the mammalian cellu-
lar response to telomere dysfunction and its consequences for cancer. Furthermore, it is
discussed how current and future knowledge about the mechanisms underlying telomere
damage responses might be applied for diagnostic purposes or therapeutic intervention.
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INTRODUCTION
Linear eukaryotic chromosomes pose multiple challenges to cells
that need to be properly taken care of to avoid loss of proliferative
capacity and genome integrity. As conventional DNA-polymerases
cannot replicate the very ends of chromosomes, each cell division
chromosome ends lose a bit of DNA-sequence, potentially causing
loss of genetic information. Furthermore, cells contain multiple
DNA-damage recognition and repair activities that act on exposed
DNA-ends to halt cell cycle progression and fix chromosome-
internal DNA-breaks to prevent unequal separation of genetic
information into daughter cells. If these activities would con-
tinuously act on natural chromosome ends, cells would not be
able to divide or properly segregate chromosomes during mitosis.
Telomeres are specialized nucleoprotein structures at chromosome
ends that cope with these challenges (de Lange, 2009; O’Sullivan
and Karlseder, 2010). By consisting of long stretches of TTAGGG
DNA-repeats and lacking genes, telomeres represent buffers that
prevent replication-associated sequence loss at chromosome ter-
mini from reaching nearby genes. Moreover, telomeres protect
natural chromosome ends from being recognized and processed
as damaged DNA. For this mammalian telomeres rely on bind-
ing shelterin, a unique set of proteins composed of TRF1, TRF2,
RAP1, TIN2, TPP1, and POT1, and on specific structural features.
Telomeres contain a 3′ G-rich single-strand overhang that binds
POT1, folds back and invades the duplex telomere repeat array.
This forms a loop (t-loop) that presumably hides the extreme end
of the chromosome from multiple activities.
While acting as buffers to prevent loss of genetic informa-
tion, telomeres themselves shorten with every round of replication
(Harley et al., 1990). Progressive shortening eventually causes
telomeres to lose their protective activity, even before all telom-
ere repeats are lost (Figure 1). Dividing cells can only avoid
telomere deprotection when able to induce sufficient activity of the
telomerase enzyme to add telomere repeats (Bodnar et al., 1998).
Alternatively cells can engage the ALT mechanism of “alternative
lengthening of telomeres” to lengthen telomeres through recom-
bination (Cesare and Reddel, 2010). Normal human somatic cells
do not have sufficient telomerase or ALT activity, which confronts
them with short dysfunctional telomeres after a certain number of
cell divisions.
Loss of telomere protection activates a DNA-damage-like sig-
naling response that through induction of tumor suppressors
p53 and p16 forces cells into senescence or apoptosis (d’Adda di
Fagagna et al., 2003; Takai et al., 2003; Jacobs and de Lange, 2004,
2005; de Lange, 2010; O’Sullivan and Karlseder, 2010). This serves
as an important tumor suppressor mechanism as it prevents the
outgrowth of potentially cancerous cells. However telomere dys-
function can also be a source of genomic instability and put cells
at risk of developing into cancer (Artandi and DePinho, 2010;
Martinez and Blasco, 2010; Davoli and de Lange, 2011; Shay and
Wright, 2011). This because DNA-repair activities at deprotected
chromosome ends generate chromosome end-to-end fusions.
In cells that escape senescence or apoptosis and divide, such
fusions initiate breakage-fusion-bridge cycles that generate com-
plex unbalanced chromosome rearrangements (Murnane, 2012).
In addition, telomere dysfunction can lead to tetraploidization and
chromosome mis-segregation (Davoli et al., 2010; Davoli and de
Lange, 2012). Thus, depending on the effectiveness of the DNA-
damage checkpoint in arresting or eliminating cells, telomere
dysfunction either inhibits or promotes the development of cancer.
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FIGURE 1 | Overview of the major consequences of loss of telomere protection in mammalian cells.
UNDERSTANDING THE CONSEQUENCES OF TELOMERE
DEPROTECTION
Multiple approaches have contributed to our current understand-
ing of the molecular events and consequences associated with loss
of telomere protection (Figure 2). These can roughly be grouped
into three categories: (1) models of telomere uncapping in mam-
malian cells or mice; (2) analyses on patient-derived material; (3)
unbiased and genome-wide approaches.
MODELS OF TELOMERE UNCAPPING IN MAMMALIAN CELLS OR MICE
Telomere uncapping occurs when telomeres become critically
short upon continued proliferation in the absence of telomerase.
Telomere dysfunction is therefore ideally studied in a replica-
tive senescence model where primary human cells are propagated
in vitro until they reach their maximum lifespan, the so-called
Hayflick limit, and stop proliferating. Analysis of the molecu-
lar changes induced at replicative senescence has yielded critical
insights, such as that critically short telomeres are recognized
by DNA-damage response (DDR) proteins (d’Adda di Fagagna
et al., 2003). Despite the advantage of following the natural course
of telomere uncapping, this approach also has limitations. One
problem is that prolonged culturing of cells in vitro is associ-
ated with culture stress inducing complex telomere-independent
cellular responses that partially overlap with telomere-mediated
responses. Equally important, telomere uncapping due to short-
ening is not a synchronous process, complicating studies on
telomere-dependent effects in a population of cells. Only a sub-
set of cells experiences critically short telomeres at a given time
and one has to wait until the majority of cells has senesced. This
precludes detection of immediate effects of telomere uncapping.
Studies on natural telomere deprotection in the context of an
entire organism face additional challenges. These are caused by the
variability in telomere lengths between individuals and between
individual cells, but also by the slow speed of telomere shorten-
ing. A particular problem arises with the use of inbred laboratory
mouse strains. While being a tremendously useful model system
to study many different biological pathways, laboratory mice are
not a good model to study the consequences of natural telomere
shortening because, unlike humans, commonly used laboratory
mouse strains have extremely long telomeres and high telomerase
activity in all cells. During their normal lifespan such mice do not
experience significant telomere uncapping (Blasco et al., 1997).
Importantly, this also implies that most studies in laboratory mice,
including those modeling cancer, do not incorporate the contri-
bution of a telomere dysfunction component that would apply to
humans.
A solution to problems associated with studying natural telom-
ere shortening came from strategies in which telomere dysfunc-
tion is experimentally induced. Following the identification of
the telomerase reverse transcriptase and RNA components and
the different shelterin factors, significant knowledge about their
function has come from experimental manipulation of telom-
erase or shelterin in tissue culture cells and mice. Apart from
proving that telomeres control replicative lifespan and affect the
development of cancer and aging-related pathologies, such stud-
ies also revealed many underlying molecular details (Artandi and
DePinho, 2010; Martinez and Blasco, 2010; Sahin and Depinho,
2010; Shay and Wright, 2011; Tumpel and Rudolph, 2012). We
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FIGURE 2 | Examples of the different experimental approaches being undertaken to understand the consequences of loss of telomere protection in
mammalian cells and the potential ways in which information from such studies might eventually be used in the clinic.
now know that telomere function depends on both unique and
redundant roles of shelterin components in protecting chromo-
some termini against six major threats: ATM-kinase activation,
ATR-kinase activation, DNA-Ligase 4- and Ku70/80-dependent
classical non-homologous end-joining (c-NHEJ), DNA-Ligase
3- and PARP-dependent alternative NHEJ (a-NHEJ), homolo-
gous recombination (HR), and end-resection (Figure 1) (Sfeir
and de Lange, 2012). Activation of ATM and ATR results in
checkpoint activation and proliferation arrest or apoptosis. c-
NHEJ generates chromosome-end-to-end fusions without appar-
ent major end-processing, leaving significant amounts of telomere
repeats at the fusion sites. On the other hand, a-NHEJ, the pri-
mary pathway causing chromosomal translocations, uses micro-
homology and results in chromosome-end-to-end fusion with
significant telomeric and subtelomeric deletion. Resection and
HR both threaten telomere integrity, the latter for instance via
unequal exchanges between sister telomeres that change telomere
length.
Of the six threats, ATM and c-NHEJ are specifically blocked
by TRF2, ATR is inhibited by POT1, while HR is inhibited by
either POT1 or RAP1, and on top by Ku70/80. On the other hand,
repression of a-NHEJ and end-resection depend on redundant
functions of shelterin and in addition are repressed by Ku70/80
and 53BP1, respectively. While the TTAGGG-repeats provided by
telomerase are needed to concentrate enough shelterin at chro-
mosome ends, telomerase activity itself is regulated by shelterin,
as well as by other factors and processes, together contributing to
complex control of telomere maintenance (Cifuentes-Rojas and
Shippen, 2012).
Studies in mice with manipulated shelterin or telomerase have
shown the consequences of telomere deprotection on an organ-
ismal level. These studies clearly illustrate the opposite effects
dysfunctional telomeres can have on the development of cancer,
depending on the DNA-damage checkpoint status and stage of
tumor development. Indeed, short telomeres in late-generation
telomerase-deficient mice protect against cancer, while predispos-
ing to aging (Greenberg et al., 1999; Rudolph et al., 1999). That is,
when DNA-damage checkpoint activity by p53 is intact. In a p53-
deficient background, where cells escape senescence or apoptosis,
short telomeres accelerate the onset of epithelial tumorigenesis
through increased genomic instability (Artandi et al., 2000). While
telomere-driven genomic instability can promote cancer initia-
tion, it can limit further cancer progression. Re-establishment
of telomere protection by activation of telomerase or ALT facil-
itates further malignant progression by genome stabilization and
improved cell viability (Begus-Nahrmann et al., 2012; Ding et al.,
2012; Hu et al., 2012).
ANALYSES ON PATIENT-DERIVED MATERIAL
Analyses of human cancers revealed that telomere shortening
is widespread during human tumorigenesis. In addition, it was
found that during their development all human tumors acti-
vate mechanisms to counteract further telomere shortening. Most
tumors activate telomerase while 10–15% of tumors activate ALT
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(Bryan et al., 1997; Shay and Bacchetti, 1997). There is mount-
ing evidence that concomitant with shortening, telomeres become
dysfunctional during human cancer development (Artandi and
DePinho, 2010). For example, anaphase bridges, a hallmark of
dysfunctional telomeres leading to genomic instability, become
more abundant at (pre)-invasive stages of colon and breast can-
cer. Moreover, in breast cancer the presence of short telomeres
coincides with a sudden rise in genomic instability at the tran-
sition from ductal hyperplasia to carcinoma in situ and before
the activation of telomerase (Chin et al., 2004). This, together
with the recent PCR-based detection of telomere fusions in early
breast cancer, provides strong evidence for the occurrence of
telomere crisis during breast cancer development (Tanaka et al.,
2012). In addition, syndromes associated with telomere replica-
tion defects, such as dyskeratosis congenita and Werner syndrome,
are characterized by short telomeres, genomic instability, and an
elevated incidence of spontaneous cancer (Armanios and Black-
burn, 2012). Similarly, diseases accompanied by increased cell
turnover, such as ulcerative colitis or liver cirrhosis, are associ-
ated with accelerated telomere shortening, telomere dysfunction,
and cancer-predisposition. However, the currently most convinc-
ing data supporting a role for telomere dysfunction in cancer
development stems from the molecular analysis of chronic lym-
phocytic leukemia (CLL) (Lin et al., 2010). A major advantage is
that this cancer allows analysis of samples from patients at dif-
ferent stages of the disease. Single-molecule telomere length and
telomere fusion analysis showed that short telomeres and fusions
increase with more advanced disease, but are already present in a
subset of patients prior to disease progression. Specifically patients
with dysfunctional telomeres, not those with longer telomeres,
were found to have large-scale genomic rearrangements concen-
trated in telomeric regions. Together the data strongly support the
model that telomere attrition and fusion contribute to the pro-
gression of CLL. Moreover, the recent discovery of frequent POT1
mutations and associated telomeric and chromosomal abnor-
malities in CLL further reinforces the involvement of telomere
dysfunction in the progression of this cancer (Ramsay et al.,
2013).
Despite all analyses on human tumors the relative contribution
of telomere deprotection to cancer development remains unclear.
While next-generation sequencing approaches rapidly generate
large amounts of data on (epi)genetic and transcriptional aber-
rations in human cancers, such approaches cannot easily reveal
how many tumors developed under facilitation by telomere-driven
genomic instability. For one, telomere repeats are filtered out dur-
ing the analysis of such sequencing data, as they cannot be mapped
to specific chromosomes. Also, current PCR-based methods do
not detect all telomere fusions. Furthermore, telomere-driven
genomic instability follows a hit-and-run mode. One single fusion
of an uncapped telomere to another uncapped telomere or a DNA-
double-strand break is sufficient to initiate breakage-fusion-bridge
cycles where subsequent breaks and fusions do not necessarily
involve telomeres but involve the entire genome. Thus both quan-
titative assessment of telomere fusion events and evaluation of the
full extent of genomic alterations triggered by telomere uncapping,
as opposed to other causes, remain difficult.
UNBIASED AND GENOME-WIDE APPROACHES
Biochemical fishing expeditions using mass-spectrometry or
yeast-two-hybrid screens have tremendously contributed to our
current knowledge about telomere biology by identifying multi-
ple factors that interact with mammalian telomeres. These con-
sist of shelterin components as well as many telomere-associated
proteins that are not considered as part of shelterin because
they have main functions outside of telomeres (Palm and de
Lange, 2008; Dejardin and Kingston, 2009; Nittis et al., 2010).
Among telomere-associated factors are nucleases, helicases, DNA-
replication proteins, DDR factors, and the CST (CTC1, STN1,
and TEN1) complex, which plays critical roles in controlling
telomeric G-overhang length, telomere replication, and telom-
erase activity (Palm and de Lange, 2008; Chen et al., 2012; Gu
et al., 2012; Sfeir, 2012; Wu et al., 2012). The finding that DDR
factors are already present at telomeres that are sufficiently long to
prevent activation of DNA-damage signaling responses was sur-
prising. Subsequent work revealed that some of these factors in
fact play protective roles. For instance Ku assists in protecting
telomeres against HR and a-NHEJ, whereas ATM and ATR have
been proposed to facilitate completion of telomere replication and
formation of a proper telomere structure (Verdun et al., 2005;
Celli et al., 2006; Verdun and Karlseder, 2006; Sfeir and de Lange,
2012).
Not all telomere-associated factors interact with telomeres con-
stantly. Some interactions are restricted to certain cell cycle phases
or specific conditions. For instance, when telomeres become crit-
ically short, some protein interactions disappear whereas new
proteins now intensively associate with telomeres, such as 53BP1
and other DDR components. Likewise, differences exist between
proteins present at telomeres maintained by telomerase versus
those present at telomeres maintained by ALT. If proteomics-
based approaches would be applied to compare different telomere
states, such as capped versus uncapped, this could significantly
increase our understanding of the mechanisms underlying con-
trol of telomere damage responses. A major challenge in such
studies is that many signaling regulators are low in abundance or
might only transiently or weakly associate with telomeres. Conven-
tional immunoprecipitation and mass-spectrometry might there-
fore have to be complemented with more sensitive techniques, such
as bimolecular fluorescent complementation that enables analy-
sis of protein interactions in living cells and has recently been
applied to identify proteins interacting with shelterin (Lee et al.,
2011).
A powerful approach that proved very successful to iden-
tify key components of multiple cellular pathways, including the
response to DNA-double-strand breaks, is gain-of-function or
loss-of-function genetic screening in mammalian cells (Jacobs
et al., 2000; Brummelkamp et al., 2004; Kolas et al., 2007; Paulsen
et al., 2009; Ashworth and Bernards, 2010; Hurov et al., 2010;
Cotta-Ramusino et al., 2011; Gudjonsson et al., 2012; Nguyen
et al., 2012). Functional genetic screening has also proven pow-
erful to identify novel telomere regulators in lower organisms,
leading for instance to implication of the yeast KEOPs com-
plex in telomere regulation (Downey et al., 2006). Since recently,
functional genetic screening is also being applied in the field
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of mammalian telomere biology. For instance, RNA-interference
screens have been initiated to identify factors involved in reg-
ulation of telomerase activity (Coussens et al., 2010; Cerone
et al., 2011), ALT (Osterwald et al., 2012), telomere protection
(Lackner et al., 2011), or telomere-driven genomic instability
(Jacobs et al., unpublished). As an example, high-throughput
RNA-interference screening identified multiple kinases, includ-
ing ERK8, with no previous association to telomere biology as
novel regulators of telomerase activity and attractive new drug
targets for cancer therapy (Cerone et al., 2011). Given the previ-
ous successes in multiple experimental settings, recently initiated
or future unbiased functional genetic screening approaches in
mammalian systems hold significant potential for identifying new
factors with important roles in the control of cancer or aging by
telomeres.
OPPORTUNITIES
TELOMERASE-BASED APPROACHES
The strong dependence on telomere maintenance for sustained
tumor growth and the presence of telomerase in 90% of can-
cers, but not most somatic cells, have inspired development of
telomerase-based strategies to inhibit cancer cell growth and
triggered evaluation of telomerase as a biomarker or prognos-
tic marker for cancer (Ruden and Puri, 2012; Mocellin et al.,
2013). Multiple telomerase-based strategies are currently evalu-
ated in clinical trials, but it is still unclear how beneficial such
strategies are to cancer patients. This is in part due to incom-
plete understanding of the effects of inhibiting telomerase on
both cancer cells and normal cells. Telomerase is important for
the renewal capacity of normal stem and progenitor cells, which
could cause unwanted side-effects. Telomerase has also been impli-
cated in telomere-independent pathways, making the outcome of
its inhibition less predictable until these pathways and roles of
telomerase therein are fully understood (Martinez and Blasco,
2011; Ghosh et al., 2012). In addition, as telomere uncapping
can cause genomic instability, there is a risk that telomerase inhi-
bition might in fact accelerate progression of some tumor cells
(Pereira and Ferreira, 2013). Moreover, dysfunctional telomeres
cause impaired mitochondrial function and promote oxidative
stress, which might lead to accumulation of additional mutations
that promote tumor progression (Sahin et al., 2011). Furthermore,
the generation of senescent cells by telomere uncapping to limit
outgrowth of the targeted tumor, comes at the cost of generating
a permissive environment for tumor progression. Namely, senes-
cent cells are known to secrete multiple factors that can promote
tumor growth and invasion of surrounding (pre-)malignant cells
(Rodier and Campisi, 2011). The risks associated with telomerase
inhibition and telomere uncapping might be less of a concern
in patients with advanced cancer, but they could limit the use
of telomerase-based strategies in young patients or patients with
early disease.
ALTERNATIVE STRATEGIES
Understanding the molecular mechanisms underlying telomere
protection, telomere-driven senescence and genomic instability
will not only increase predictability and understanding of the
efficacy of telomerase-based strategies, but will also facilitate
development of novel therapeutic strategies for cancer and (pre-
mature) aging-related disease (Figure 2). For cancer these could
aim to provoke senescence, as with telomerase inhibition. How-
ever, particularly interesting would be to think of alternative
strategies that avoid unwanted side-effects or risks of existing
approaches, such as associated with induction of senescence. A
potential, but challenging strategy could be to inhibit telomere-
driven genomic instability before obvious cancer presentation
to prevent or slow down cancer development. This might for
instance be applied to people predisposed to cancer because of
a condition associated with accelerated telomere shortening. Inhi-
bition of telomere-driven genomic instability could be achieved by
inhibiting telomere fusion by interfering with DNA-repair activ-
ities at uncapped telomeres. Such a strategy should not impair
regular error-free DNA-repair at other sites, to avoid increas-
ing cancer risk. An intriguing opposite strategy might in fact
be to increase genomic instability such that cancer cells die of
crisis, by “tipping the balance.” High levels of genomic instabil-
ity, that may drive initiation of early lesions, need to be reduced
to allow efficient tumor progression. Nevertheless, many cancers
are hallmarked by an instable genome, hyper-sensitizing them
to genome-destabilizing strategies. Interestingly, increased and
ongoing chromosomal instability is also common for tumors
utilizing ALT, along with telomeres that are recognized as DNA-
damage, but appear not to fuse (Scheel et al., 2001; Cesare et al.,
2009; Lovejoy et al., 2012). Besides interfering with the ALT
mechanism, alleviating repression of telomere fusion might be
an effective way to kill ALT tumor cells by inducing rampant
genomic instability. This is an especially intriguing possibility
given that ALT tumors do not rely on telomerase for telomere
maintenance and would thus be resistant to telomerase-based
therapeutics.
The development and adequate application of such new ther-
apeutic strategies, require thorough investigation and under-
standing of the mechanisms underlying control of DDR and
repair activities at telomeres and DNA-lesions. Apart from reveal-
ing new drug targets, studies addressing this might also con-
tribute to prediction of therapy responses to DNA-damage
inducing anti-cancer drugs or to development of strategies to
enhance cancer drug sensitivity. With respect to the latter, it
is interesting to note that dysfunctional telomeres have been
shown to increase the sensitivity of cells to ionizing radiation
and DNA-damaging chemotherapeutics (Wong et al., 2000; Lee
et al., 2001; Soler et al., 2009). In addition, insights into the
precise events associated with telomere uncapping could con-
tribute to the establishment of diagnostic tools, such as for early
detection of cancers and identification of cancer-predisposed
individuals.
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